Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363–85.

Article  PubMed  Google Scholar 

Bhatia S. Genetics of anthracycline cardiomyopathy in cancer survivors. JACC: CardioOncology. 2020;2(4):539–52.

PubMed  PubMed Central  Google Scholar 

Basak D, Gamez D, Deb S. SGLT2 inhibitors as potential anticancer agents. Biomedicines. 2023;11(7):1867.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu W, Wang Y, Xie J, Fan S. Empagliflozin: a potential anticancer drug. Discov Oncol. 2023;14(1):127.

Article  PubMed  PubMed Central  Google Scholar 

Armenian SH, Hudson MM, Mulder RL, et al. Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol. 2015;16(3):e123–36.

Article  PubMed  PubMed Central  Google Scholar 

Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J. 2022;43(41):4229–361.

Article  PubMed  Google Scholar 

Henriksen PA, Rankin S, Lang NN. Cardioprotection in patients at high risk of anthracycline-induced cardiotoxicity. JACC: CardioOncology. 2023;5(3):292–7.

PubMed  PubMed Central  Google Scholar 

Chang H-M, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular complications of cancer therapy. J Am Coll Cardiol. 2017;70(20):2536–51.

Article  PubMed  PubMed Central  Google Scholar 

Chang H-M, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1. J Am Coll Cardiol. 2017;70(20):2536–51.

Article  PubMed  PubMed Central  Google Scholar 

Henriksen PA, Rankin S, Lang NN. Cardioprotection in patients at high risk of anthracycline-induced cardiotoxicity: JACC: CardioOncology Primer. JACC: CardioOncology. 2023;5(3):292–7.

PubMed  PubMed Central  Google Scholar 

Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18(11):1639–42.

Article  PubMed  Google Scholar 

Jirkovský E, Jirkovská A, Bavlovič-Piskáčková H, et al. Clinically translatable prevention of anthracycline cardiotoxicity by dexrazoxane is mediated by topoisomerase II beta and not metal chelation. Circ Heart Fail. 2021;14(11):e008209.

Article  PubMed  Google Scholar 

Baldassarre LA, Ganatra S, Lopez-Mattei J, et al. Advances in multimodality imaging in cardio-oncology: JACC state-of-the-art review. J Am Coll Cardiol. 2022;80(16):1560–78.

Article  PubMed  Google Scholar 

Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, et al. Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2021;77(3):243–55.

Article  CAS  PubMed  Google Scholar 

Yurista SR, Chong C-R, Badimon JJ, et al. Therapeutic potential of ketone bodies for patients with cardiovascular disease. J Am Coll Cardiol. 2021;77(13):1660–9.

Article  CAS  PubMed  Google Scholar 

Usman MS, Siddiqi TJ, Anker SD, et al. Effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations. J Am Coll Cardiol. 2023;81(25):2377–87.

Article  CAS  PubMed  Google Scholar 

Dutka M, Bobiński R, Francuz T, et al. SGLT-2 inhibitors in cancer treatment-mechanisms of action and emerging new perspectives. Cancers (Basel). 2022;14(23). https://doi.org/10.3390/cancers14235811.

Sabatino J, De Rosa S, Tammè L, et al. Empagliflozin prevents doxorubicin-induced myocardial dysfunction. Cardiovasc Diabetol. 2020;19(1):66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Faggiano A, Gherbesi E, Cardinale D, Vicenzi M, Carugo S. SGLT2-i prevent left ventricular dysfunction induced by anthracycline in mouse model: a systematic-review and meta-analysis. Vasc Pharmacol. 2023;150:107171.

Article  Google Scholar 

Oh CM, Cho S, Jang JY, et al. Cardioprotective potential of an SGLT2 inhibitor against doxorubicin-induced heart failure. Korean Circ J. 2019;49(12):1183–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barış VÖ, Dinçsoy AB, Gedikli E, et al. Empagliflozin significantly prevents the doxorubicin-induced acute cardiotoxicity via non-antioxidant pathways. Cardiovasc Toxicol. 2021;21(9):747–58.

Article  PubMed  Google Scholar 

Quagliariello V, De Laurentiis M, Rea D, et al. SGLT2 inhibitor dapagliflozin against anthracycline and trastuzumab-induced cardiotoxicity: the role of MYD88, NLRP3, Leukotrienes/Interleukin 6 axis and mTORC1 /Fox01/3a mediated apoptosis. Eur Heart J. 2020;41(Supplement_2). https://doi.org/10.1093/ehjci/ehaa946.3253.

Scafoglio C, Hirayama BA, Kepe V, et al. Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci. 2015;112(30):E4111–E9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–61.

Article  CAS  PubMed  Google Scholar 

Giangiacomi F, Faggiano A, Cardinale D, et al. Case report: Sodium-glucose cotransporter 2 inhibitors induce left ventricular reverse remodeling in anthracycline-related cardiac dysfunction—a case series. Front Cardiovasc Med. 2023;10. https://doi.org/10.3389/fcvm.2023.1250185.

Gongora CA, Drobni ZD, Silva TQAC, et al. Sodium-glucose co-transporter-2 inhibitors and cardiac outcomes among patients treated with anthracyclines. JACC: Heart Failure. 2022;10(8):559–67.

PubMed  Google Scholar 

McGovern AP, Hogg M, Shields BM, et al. Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ Open Diabetes Res Care. 2020;8(1):e001238.

Article  PubMed  PubMed Central  Google Scholar 

Abdel-Qadir H, Carrasco R, Austin PC, et al. The association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcomes in anthracycline-treated patients with cancer. JACC: CardioOncology. 2023;5(3):318–28.

PubMed  PubMed Central  Google Scholar 

Chiang C-H, Chiang C-H, Chiang C-H, et al. Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer. Heart. 2023;109(6):470–7.

Article  PubMed  Google Scholar 

Avula V, Sharma G, Kosiborod MN, et al. SGLT2 inhibitor use and risk of clinical events in patients with cancer therapy–related cardiac dysfunction. JACC: Heart Failure. 2024;12(1):67–78.

PubMed  Google Scholar 

Perelman MG, Brzezinski RY, Waissengrin B, et al. Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors. Cardio-Oncology. 2024;10(1):2.

Article  PubMed  PubMed Central  Google Scholar